Colonoscopy performance may be improved with knowledge of positive cologuard test results: study

Clean Sweep Live Auction on Wed. Sep. 18th. Click to view the full inventory


Colonoscopy performance may be improved with knowledge of positive cologuard test results: study

Press releases may be edited for formatting or style | May 23, 2016
May 23, 2016 -- MAYO CLINIC -- SAN DIEGO - An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation at last week's Digestive Disease Week conference.

Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the U.S. Food and Drug Administration. This test, available by prescription only, is reimbursed by Medicare and covered by an increasing number of commercial health care plans.

Researchers from Mayo Clinic compared results of colonoscopies following a positive result from Cologuard (unblinded) with colonoscopies performed by those who were not aware of the Cologuard result (blinded). Unblinded endoscopists found polyps or hemorrhagic lesions 83 percent of the time and precancerous polyps in 70 percent of patients, compared to 68 and 53 percent of blinded endoscopists, respectively.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

"Endoscopist knowledge of a positive Cologuard result appears to enhance colonoscopy quality, based on observed differences in number of detected lesions, total adenomas, detection of inconspicuous or flat lesions, and withdrawal times." says David Johnson, M.D., a gastroenterologist at Mayo Clinic's Rochester campus. "This increase in yield could translate into more true-positive and fewer false-negative results than estimated from blinded pre-approval studies." The study also showed that unblinded endoscopists spent 46 percent more time and found twice as many polyps per colonoscopy.

The blinded group included a portion of the Cologuard-positive patients who participated in the DeeP-C clinical study, which was published in the April 2014 New England Journal of Medicine. The DeeP-C study evaluated Cologuard's performance in nearly 10,000 patients. Cologuard was found to be 92 percent sensitive in detecting colorectal cancer with 87 percent specificity.

In August 2014, Mayo Clinic became the health care organization to offer Cologuard. The Cologuard technology platform was co-developed by Exact Sciences Corp. and Mayo Clinic as part of a broad, exclusive collaboration.


David Ahlquist, M.D., a Mayo Clinic gastroenterologist is co-inventor of the test.

Dr. Ahlquist and Mayo Clinic have a financial interest in Cologuard. Neither Mayo Clinic nor Dr. Ahlquist receives royalties for Cologuard tests ordered for Mayo patients by Mayo physicians.

About Exact Sciences

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. For more information, follow Exact Sciences on Twitter @ExactSciences, or on Facebook.

You Must Be Logged In To Post A Comment